Alx oncology to present updated results from phase 2 aspen-06 clinical trial of evorpacept in patients with her2-positive gastric cancer in oral presentation at 2025 asco gastrointestinal cancers symposium

South san francisco, calif., dec. 18, 2024 (globe newswire) -- alx oncology holdings inc. (“alx oncology” or “the company”) (nasdaq: alxo), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that the updated results from its phase 2 aspen-06 clinical trial have been accepted for oral presentation at the 2025 american society of clinical oncology (asco) gastrointestinal cancers symposium, which will be held in san francisco from january 23 - 25, 2025.
ALXO Ratings Summary
ALXO Quant Ranking